Here's Why Analysts are Bullish on Soleno Therapeutics (SLNO)

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. The company announced several positive developments in its fiscal second quarter 2025 business update.

It announced the commercial launch of VYKAT XR during the quarter, which is the first FDA-approved treatment for hyperphagia in Prader-Willi Syndrome. Management noted that since the approval, the company has received 646 patient start forms from 295 unique prescribers, covering over 100 million insured lives in the US. Moreover, the company is also seeking marketing approval for VYKAT XR in the European Union through the European Medicines Agency and has presented clinical data at major medical conferences to raise awareness about the drug’s safety and efficacy.

Analysts have been bullish on the stock. On September 4, TD Cowen analyst Tyler Van Buren maintained a Buy rating on Soleno Therapeutics, Inc. (NASDAQ:SLNO), with a price target of $120. Earlier, on August 25, Leland Gershell from Oppenheimer also reiterated a Buy rating on the stock with a price target of $110.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a biopharmaceutical company that develops and commercializes novel treatments for rare diseases.

While we acknowledge the potential of SLNO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.